Esti aici
Acasa => Coronavirus COVID-19 => Evidence conflicts over efficacy of monoclonal antibodies in severe COVID

Evidence conflicts over efficacy of monoclonal antibodies in severe COVID

Feb 26, 2021

„We are left with evidence of benefit from interleukin-6 inhibitors, at least under some circumstances.”

Powered by WPeMatico

Articole similare

Sus
%d blogeri au apreciat: